Alnylam Announces Update on its Board of Directors

Alnylam Pharmaceuticals, Inc.

, a leading RNAi therapeutics company, announced today the election of Steven M. Paul, M.D., to its Board of Directors. Dr. Paul is the former President of the Lilly Research Laboratories of Eli Lilly and Company. Alnylam also announced the retirement of James L. Vincent, the former Chief Executive Officer and Chairman of Biogen Idec, Inc. “We are very excited to have Steve join the Alnylam Board. Steve is widely recognized as a leader across many dimensions of medical research and drug development, and he will bring this critical expertise to our Board as we advance our innovative medicines to patients,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “We are very grateful to Jim for his insightful service as an Alnylam Director. We wish him all the best in his retirement.” “The field of RNAi therapeutics represents an opportunity to create an entirely new class of high impact medicines, with broad applications for the treatment of human disease,” said Dr. Paul. “I am very excited to be a part of the important work that Alnylam is doing and look forward to working with the outstanding team in place and contributing to this effort.”